Work

REVERCEII (ACCRU-GI-1809): A randomized phase II study of regorafenib followed by anti-EGFR monoclonal antibody therapy versus the reverse sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.4_suppl.tps213

Authors: Daniel H. Ahn, Fang-Shu Ou, Bassam Bassam Sonbol, Donald Wender, Kelsey Klute, Zhaohui Jin, Jeremy Clifton Jones, Angela Ulrich, Blake Waechter, Heather Young, Benjamin Adam Weinberg, Heinz-Josef Lenz, John H. Strickler, Tanios S. Bekaii-Saab

Institutions: Mayo Clinic, Mayo Clinic in Arizona, Mayo Clinic Hospital, Mayo Clinic Comprehensive Cancer Center (Arizona), June E. Nylen Cancer Center, University of Nebraska Medical Center, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, University of Southern California, USC Norris Comprehensive Cancer Center, Duke University, Duke Medical Center

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4206117127

Cites:

Cited by:

Related to: 10